EASL 2015: International Liver Congress Now Underway in Vienna

alt

The European Association for the Study of the Liver's International Liver Congress (EASL 2015) takes place April 22-26 at the Reed Messe Wien Centre in Vienna, Austria. The annual meeting -- one of the key scientific conferences covering hepatitis B and C and its complications -- is observing its 50th year. Look for breaking news coverage from HIVandHepatitis.com and our partners at Aidsmap.com starting Friday at www.HIVandHepatitis.com and via @HIVandHepatitis on Twitter. Abstracts and other information are available on the International Liver Congress website.

The development of direct-acting antiviral agents that can be used in interferon-free regimens has brought about a revolution in hepatitis C treatment, and this has been a key focus of the International Liver Congress in recent years. With several of these drugs now approved in a number of countries and more coming down the pipeline, refining their use -- especially for difficult-to-treat patient populations -- and increasing access remains a major topic.

In addition to further studies of Gilead Sciences' sofosbuvir (Sovaldi) and sofosbuvir/ledipasvir (Harvoni), AbbVie's Viekira Pak regimen, Janssen's simeprevir (Olysio), and Bristol-Myers Squibb's daclatasvir (Daklinza), researchers will present data from several clinical trials of Merck's grazoprevir/elbasvir combination, which is expected to be submitted for FDA approval by the middle of this year.

Other research to be presented at the conference includes new therapies for hepatitis B, non-alcoholic fatty liver disease, and management of liver disease complications including cirrhosis, liver cancer, and liver transplantation.

4/22/15

Source

EASL. International Liver Congress.https://ilc-congress.eu/ilc-2015.